Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022010273 - FUSION PROTEINS COMPRISING COMPLEMENT PATHWAY INHIBITOR AND USE THEREOF

Publication Number WO/2022/010273
Publication Date 13.01.2022
International Application No. PCT/KR2021/008683
International Filing Date 07.07.2021
IPC
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 27/02 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
Applicants
  • 주식회사 카나프테라퓨틱스 KANAPH THERAPEUTICS INC. [KR]/[KR]
Inventors
  • 정으뜸 CHUNG, Eu Ddeum
  • 유수민 RYU, Soomin
  • 김동건 KIM, Donggeon
  • 장지훈 CHANG, Jihoon
  • 이병철 LEE, Byoung Chul
Agents
  • 류종우 RYU, Jong Woo
  • 이내영 LEE, Rae Young
  • 한윤호 HAN, Yun Ho
Priority Data
10-2020-008353607.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) FUSION PROTEINS COMPRISING COMPLEMENT PATHWAY INHIBITOR AND USE THEREOF
(FR) PROTÉINES DE FUSION COMPRENANT UN INHIBITEUR DE LA VOIE DU COMPLÉMENT ET LEUR UTILISATION
(KO) 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
Abstract
(EN) Provided is a fusion protein comprising: an extracellular domain of CRIg or a fragment thereof; and CD59 or a mutant thereof. Also, a fusion protein comprising CD59 or a mutant thereof is provided. The proteins can efficiently regulate complement-related pathways. Thus, the fusion protein dimers can be effectively used in the treatment and prevention of eye diseases, particularly macular degeneration, and therefore are highly industrially applicable.
(FR) L'invention concerne une protéine de fusion comprenant : un domaine extracellulaire de CRIg ou un fragment de celui-ci ; et CD59 ou un mutant de celui-ci. L'invention concerne également une protéine de fusion comprenant CD59 ou un mutant de celui-ci. Les protéines peuvent réguler efficacement les voies liées au complément. Ainsi, les dimères de protéines de fusion peuvent être efficacement utilisés dans le traitement et la prévention de maladies oculaires, en particulier la dégénérescence maculaire, et sont par conséquent hautement applicables industriellement.
(KO) CRIg의 세포외도메인 또는 이의 단편; 및 CD59 또는 이의 변이체를 포함하는 융합단백질을 제공한다. 또한, CD59 또는 이의 변이체를 포함하는 융합단백질을 제공한다. 상기 단백질은 보체 관련 경로를 효율적으로 조절할 수 있다. 따라서, 상기 융합단백질 이량체는 안질환, 특히 황반 변성의 치료 및 예방에 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다.
Latest bibliographic data on file with the International Bureau